Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies and Estimates (Tables)

Summary of Significant Accounting Policies and Estimates (Tables)

12 Months Ended

Dec. 31, 2015

Schedule of basic and diluted net income (loss) per share

Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of common stock, adjusted to include conversion of certain stock options and warrants for common stock during the period, as follows:

	Years ended December 31,
	2015		2014		2013
Numerator:
Net loss applicable to common stockholders
Basic	$	(24,245)	$	(33,769)	$	(11,887)
Adjustment for gain on fair value of warrant liability		(2,505)		-		-
Diluted	$	(26,750)	$	(33,769)	$	(11,887)

Denominator
Weighted-average number of shares for basic net loss per share		102,241		78,264		20,977
Effect of dilutive shares		24		-		-
Weighted-average number of shares for dilutive net loss per share		102,265		78,264		20,977

Net loss per share
Basic	$	(0.24)	$	(0.43)	$	(0.57)
Diluted	$	(0.26)	$	(0.43)	$	(0.57)

Schedule of Antidilutive Securities

The following potential dilutive securities were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive:

	Years ended December 31,
	2015		2014		2013
Options to purchase common stock		13,743		10,791		7,555
Warrants for common stock		13,745		13,796		1,389
Common stock issuable upon conversion of preferred shares		13,131		-		-
Total common stock equivalents		40,619		24,587		8,944